首页> 外文期刊>Radiology and Oncology >Postoperative radiochemotherapy for gastric adenocarcinoma: long term results
【24h】

Postoperative radiochemotherapy for gastric adenocarcinoma: long term results

机译:胃腺癌术后放化疗:长期结果

获取原文
           

摘要

Background. To analyze the efficacy of postoperative radiochemotherapy with 5-florouracil (5-FU) and leucovorin (LV) applied in the patients with gastric carcinoma treated in a single institution.Patients and methods. Between 2001 and 2004, 123 patients with resected gastric adenocarcinoma were treated with postoperative concomitant radiochemotherapy with 5-FU and LV. The adjuvant treatment consisted of five cycles of chemotherapy with 5-FU (425mg/m2 IV) and LV (20 mg/m2 IV) and concomitant radiotherapy with the total dose of 45 Gy.Results. The treatment was completed according to the protocol in 82% of patients. The frequency and severity of early toxic effects induced by radiochemotherapy were manageable. Median follow-up time of 56 survivors was 64.5 months (range: 51.7-96.4 months). The 5-year locoregional control (LRC), disease-free survival (DFS), disease-specific survival (DSS) and overall survival (OS) were 81%, 48.3%, 50.4%, and 48.4%, respectively. The multivariate analysis showed that the tumor involvement of cardia and low intensity of chemotherapy were independent adverse prognostic factors for DSS and OS. More advanced pT-stage and tumors with diffuse growth type according to Lauren were identified as negative independent prognostic factor for OS. They were also on the threshold of statistical significance for DSS.Conclusions. Postoperative radiochemotherapy for gastric carcinoma has acceptable toxicity, and is effective particularly in regard to LRC. High incidence of distant metastases calls for more effective systemic regimens.
机译:背景。分析5-氟尿嘧啶(5-FU)和亚叶酸(LV)在单一机构接受治疗的胃癌患者术后放化疗的疗效。方法和患者。在2001年至2004年之间,对123例切除的胃腺癌患者进行了术后伴有5-FU和LV放疗。辅助治疗包括5个周期的5-FU(425mg / m2 IV)和LV(20 mg / m2 IV)化疗以及伴随放疗,总剂量为45 Gy。根据协议,该治疗已在82%的患者中完成。放化疗引起的早期毒性作用的频率和严重程度是可以控制的。 56名幸存者的中位随访时间为64.5个月(范围:51.7-96.4个月)。 5年局部区域对照(LRC),无病生存期(DFS),疾病特异性生存期(DSS)和总生存期(OS)分别为81%,48.3%,50.4%和48.4%。多元分析表明,of门癌累及低强度化疗是DSS和OS的独立不良预后因素。 Lauren认为更晚期的pT分期和具有弥漫性生长类型的肿瘤被确定为OS的阴性独立预后因素。他们还处于DSS的统计显着性阈值上。结论。胃癌的术后放射化学疗法具有可接受的毒性,并且对于LRC特别有效。远处转移的高发生率要求更有效的全身疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号